Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks

Hepatitis B

Interferon

Interferon+resveratrol

The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients

The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial.

First Hospital of Jilin University

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.

Metastatic Cancer

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Non Chemotherapy

Chemotherapy and target therapy

Chinese herb medicine

Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of medicine

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Clinical Studies by Using Alphacait to Screen Drug Combinations for Advanced Solid Tumor

Progression-free survival (PFS) is defined as the time from assignment in the trial to disease progression or death from any cause.

Defined as the time from assignment to death from any cause.

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response or stable disease to therapy

Drug-related adverse reactions must be recorded, mainly in the following：myelosuppression including neutropenia, anemia and thrombocytopenia;Cardiac toxicity; muscle fatigue, pain, imbalance; Oral ulcers: the patient's gums, cheeks, throat and tongue are prone to ulcers;nausea, vomiting, constipation or diarrhea;hair loss;skin discomfort;hormonal fluctuations, sexual dysfunction, infertility; damage of the kidney;anxiety and depression.

Expectations of exploratory markers for this study include the status of exploratory biomarkers associated with immunohistochemistry (IHC) or quantitative reverse transcription polymerase chain reaction (qRT-PCR), a new generation sequencing method (NGS), Nanostring technique and / or other methods to evaluate archived and/or newly acquired tumor tissue, as well as its association with disease status and/or (Including but not limited to somatic mutations and other exploratory markers) according to qRT-PCR and NGS techniques, and to evaluate the relationship between the therapeutic response, the status of the biomarker during exploratory treatment and during treatment, and the evaluation of plasma, serum or whole blood samples (including but not limited to somatic mutations and other exploratory markers) The association of the above markers with disease status and / or therapeutic response.

Through publication after study completion

Haining Health-Coming Biotech Co., Ltd.

Alphacait, LLC

This single center, open-label, single arm, non-randomized study is designed to evaluate safety, progression-free survival(PFS),overall survival (OS), objective response rate (OPR), and disease control rate (DCR) of chemotherapy or target therapy or chinese medicine based on the Alphacait screening system in subjects with advanced malignant tumor.

drug:entecavir 0.5mg/day, one time/day,144weeks

entecavir 0.5mg/day, 144weeks intervention:resveratrol 1000mg/day, 48weeks

entecavir 0.5mg/day, 144weeks thymosin α1 2 times/week, 24weeks

Hepatitis

entecavir+resveratrol

Entecavir

entecavir+thymosin α1

The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial

HBsAg loss rate, decline and seroconversion rate

Junqi Niu

MD, PhD

Chinese Academy of Sciences

Subjects in the group "resveratrol first" will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting).

Subjects in the group "Placebo first" will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting).

Chronic Subclinic Inflammation

Redox Status

Subjects in the group "resvetarol first" will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting).

Resveratrol

resveratrol

Simona Bo

Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.

Double-blind Cross-over Randomised Controlled Trial on the Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.

To evaluate before-after changes in circulating concentrations of C-reactive protein (CRP), an inflammation marker, in smokers submitted to resveratrol supplementation when compared to smokers treated with placebo

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: TAS (total antioxidant status.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: 4-hydroxynonenal

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: nitrotyrosine.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: endothelial nitric oxide synthase (eNOS)-polymorphism

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: superoxide dismutase (SOD2)-polymorphism.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: catalase-polymorphism

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-other markers of inflammation: interleukin-6.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-other markers of inflammation: pentraxin 3.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-other markers of inflammation: tumor necrosis factor-α.

reynoutria/protiplesňový

The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.

Najkompletnejšia databáza liečivých bylín podporovaná vedou